Gilead

Aug 29, 2018

National health authorities, U.K.'s NICE determines Gilead's cancer cell therapy exorbitant The National Institute for Health and Care Excellence (NICE) found Gilead's cancer cell therapy, Yescarta to be clinically efficacious for treating a type of lymphoma, but no ample evidence is present to estimate the benefit...

Aug 23, 2018

AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, ...

Mar 13, 2018

Anthera’s Sollpura flops after phase 3   Anthera cut free it’s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared "key choices". Sollpura was out-licensed by Lilly in 2014, and the written work had all the attributes of its failure, back in December 2016 when it posted the info...

Jul 11, 2017

Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports Gilead Sciences thought it had prevailed in a whistleblower lawsuit alleging it circumvented FDA rules to use a China-made active ingredient in three top HIV meds, rather than a higher-priced version from South Korea that the agency had a...

Mar 01, 2017

The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in thos...

Aug 18, 2016

Branded product portfolio of Shionogi acquired by Lupin Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product portfolio of Japan’s Shionogi & Co., Ltd. The agreement results in acquisition of 21 products long-listed, and the dea...